EntryPoint Capital LLC Invests $299,000 in Delcath Systems, Inc. (NASDAQ:DCTH)

EntryPoint Capital LLC purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 24,816 shares of the company’s stock, valued at approximately $299,000.

Several other institutional investors and hedge funds have also bought and sold shares of DCTH. Polar Asset Management Partners Inc. bought a new position in Delcath Systems in the 3rd quarter valued at about $1,594,000. Principal Financial Group Inc. bought a new position in Delcath Systems in the third quarter valued at approximately $808,000. Virtu Financial LLC bought a new position in Delcath Systems in the third quarter valued at approximately $289,000. Simplify Asset Management Inc. acquired a new position in Delcath Systems during the fourth quarter valued at approximately $205,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in Delcath Systems during the fourth quarter worth $204,000. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Performance

Shares of DCTH opened at $13.40 on Friday. The stock has a market capitalization of $447.60 million, a price-to-earnings ratio of -9.93 and a beta of 0.82. Delcath Systems, Inc. has a 52 week low of $4.26 and a 52 week high of $16.97. The stock has a fifty day moving average of $14.61 and a 200-day moving average of $11.99.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The firm had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.96 million. During the same quarter in the prior year, the business posted ($0.48) earnings per share. As a group, equities analysts forecast that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Wall Street Analyst Weigh In

DCTH has been the topic of several recent analyst reports. HC Wainwright lifted their price target on Delcath Systems from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, March 7th. Craig Hallum lifted their target price on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.75.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.